=> s l3
L4 14 L3

=> d abs bib fhitstr 1-14

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
AB The present invention related to a combination of (a) a GSK3 inhibitor and (b) an α7- nicotinic agonist. The invention further relates to pharmaceutical compns. comprising said combination and to methods of treating CNS disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kits in treatment of CNS disorders such as dementia and/or Alzheimer's Disease.
AN 2009:138859 CAPLUS
DN 150:222260
TI New therapeutic combination of a glycogen synthase kinase-3 (GSK3) inhibitor and an α7-nicotinic agonist
IN Basun, Hans; Cox, Graham; Nordgren, Ingrid
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 59pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009017454	A1	20090205	WO 2008-SE50897	20080729
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2007-952651P	P	20070730		

IT 220099-94-5
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(combination of a glycogen synthase kinase-3 (GSK3) inhibitor and an α7-nicotinic agonist for dementia therapy)
RN 220099-94-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl-

(CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN

AB A method of treating ileus in a subject by administering to the subject an effective amount of a pharmacol. agent that increases the activity of cholinergic receptor in a subject is described. Examples of pharmacol. agents are brain muscarinic agonist, cholinergic agonist or cholinesterase inhibitor. The methods of the present invention can be used to treat ileus caused by abdominal surgery, or administration of narcotics or chemotherapeutic agents such as during cancer chemotherapy.

AN 2006:13528 CAPLUS

DN 144:101040

TI Method of treating ileus by pharmacological activation of cholinergic receptors

IN Tracey, Kevin J.; Fink, Mitchell P.

PA North Shore-Long Island Jewish Research Institute, USA; University of Pittsburgh- Higher Education Of the Commonwealth System

SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006002375	A2	20060105	WO 2005-US22495	20050623
	WO 2006002375	A3	20060629		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005258274	A1	20060105	AU 2005-258274	20050623
	CA 2571584	A1	20060105	CA 2005-2571584	20050623
	EP 1773304	A2	20070418	EP 2005-763466	20050623
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008504282	T	20080214	JP 2007-518311	20050623

US 20070213350 A1 20070913 US 2006-645120 20061222
PRAI US 2004-582545P P 20040623
WO 2005-US22495 W 20050623
OS MARPAT 144:101040
IT 521288-83-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(activation of cholinergic receptors by muscarinic agonist, cholinergic agonist or cholinesterase inhibitor for treatment of ileus)
RN 521288-83-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
AB Disclosed is a method of reducing bleed time in a subject by activation of the cholinergic anti-inflammatory pathway in said subject. The cholinergic anti-inflammatory pathway can be activated by direct or indirect stimulation of the vagus nerve. The cholinergic anti-inflammatory pathway can also be activated by administering an effective amount of cholinergic agonist acetylcholinesterase inhibitor to the subject. Examples were given for reduction of bleed time in a mouse model with elec. stimulation of the vegus nerve or nicotine administration.
AN 2005:1075611 CAPLUS
DN 143:339670
TI Neural tourniquet with activation of cholinergic anti-inflammatory pathway
IN Tracey, Kevin J.; Amella, Carol A.; Czura, Christopher
PA North Shore-Long Island Jewish Research Institute, USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005092308	A2	20051006	WO 2005-US9954	20050324
WO 2005092308	A3	20051201		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2005225458	A1	20051006	AU 2005-225458	20050324
AU	2005225458	B2	20081204		
CA	2560756	A1	20051006	CA 2005-2560756	20050324
US	20050282906	A1	20051222	US 2005-88683	20050324
EP	1734941	A2	20061227	EP 2005-755668	20050324
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP	2007530586	T	20071101	JP 2007-505209	20050324
PRAI US	2004-556096P	P	20040325		
	WO 2005-US9954	W	20050324		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 143:339670

IT 521288-83-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neural tourniquet with activation of cholinergic anti-inflammatory pathway)

RN 521288-83-5 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN

AB Potent and selective ligands of the α7 nicotinic acetylcholine receptor are required to understand the pharmacol. effect of α7 activation. A common cross-reactivity occurs with serotonergic 5-HT3 receptors with which α7 receptors have a high sequence homol. The authors demonstrate that certain quinuclidine 3-biaryl carboxamides are high affinity α7 ligands with an excellent binding selectivity over 5-HT3 receptors.

AN 2005:1024915 CAPLUS

DN 143:452150

TI High affinity ligands for the α7 nicotinic receptor that show no cross-reactivity with the 5-HT3 receptor

AU Baker, S. Richard; Boot, John; Brunavs, Michael; Dobson, David; Green, Rachel; Hayhurst, Lorna; Keenan, Martine; Wallace, Louise

CS Lilly Research Centre, Eli Lilly and Company Ltd., Surrey, GU20 6PH, UK

SO Bioorganic & Medicinal Chemistry Letters (2005), 15(21), 4727-4730
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal
LA English
OS CASREACT 143:452150
IT 521288-83-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(high affinity ligands for α7 nicotinic receptor showing no cross-reactivity with 5-HT3 receptor)
RN 521288-83-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
AB A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compds. of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-Et ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulas (I), (II), (III) and (IV) are described herein.
AN 2005:547267 CAPLUS
DN 143:71763
TI Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
IN Tracey, Kevin J.; Wang, Hong
PA North Shore Long-Island Jewish Research Institute, USA; The Feinstein Institute for Medical Research
SO U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 729,427.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 20050137218 A1 20050623 US 2004-957426 20040930
US 7238715 B2 20070703
US 20040204355 A1 20041014 US 2003-729427 20031205
US 7273872 B2 20070925
EP 1949901 A2 20080730 EP 2007-20473 20031205
EP 1949901 A3 20081015
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR
EP 2062595 A1 20090527 EP 2009-1425 20031205
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR
US 20090123456 A1 20090514 US 2007-724605 20070315
PRAI US 2002-431650P P 20021206
US 2003-729427 A2 20031205
EP 2003-796701 A3 20031205
EP 2007-20473 A3 20031205
US 2004-957426 A1 20040930
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
IT 220099-94-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of pancreatitis using α7 receptor-binding cholinergic agonists)
RN 220099-94-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
AB The α7 nicotinic acetylcholine receptor is highly expressed in the brain and has been associated with both psychotic and cognitive disorders. This receptor might therefore represent a potential target for novel drugs. We have studied the pharmacol. properties of two new α7 agonists, referred to as A ((R)-(-)-5'-phenylspiro[1-azabicyclo[2,2,2]octane]-3,2'-(3'H)furo[2,3-b]pyridine) and B ((R)-N-(1-azabicyclo[2,2,2]oct-3-yl)-5-(2-pyridyl)thiopene-2-carboxamide). Both compds. activate human α7 nAChRs without activating other nAChR subtypes. When these selective α7 nAChR agonists were evaluated in behavioral assays, no activity of these compds. was detected (O'Neill et al., 2002). It is known that nAChRs can be desensitized by lower concns. of agonist than those needed to activate them. We have measured the concentration-response curves of these compds. to both activate and to cause steady-state desensitization of α7 nAChRs. Both compds. desensitize α7 nAChRs at much lower concns. than the concns. which activate

them. This might be one of the reasons for the lack of effects of these compds. in in vivo behavioral assays.

AN 2005:332477 CAPLUS
DN 143:1059
TI Functional characterization of selective α7 nicotinic acetylcholine receptor agonists
AU McPhie, G. I.; Pearson, K. P.; Broadmore, R. J.; Cases, M.; Kennan, M.; Boot, J. R.; Baker, S. R.; Broad, L. M.; Sher, E.; Zwart, R.
CS Lilly Research Centre, Eli Lilly & Company Limited, Windlesham, Surrey, UK
SO Proceedings of the FEPS Congress, 3rd, Nice, France, June 28-July 2, 2003 (2003), 189-193. Editor(s): Poujeol, Philippe; Petersen, Ole. Publisher: Monduzzi Editore, Bologna, Italy.
CODEN: 69GUDS; ISBN: 88-323-3144-6
DT Conference; (computer optical disk)
LA English
IT 521288-83-5
RL: PAC (Pharmacological activity); BIOL (Biological study)
(functional characterization of selective α7 nicotinic acetylcholine receptor agonists)
RN 521288-83-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of isotope-labeled spiro(azabicyclooctane-furopyridine) derivs. of formula I [wherein: Ar is 6-membered (un)substituted aromatic ring with 0-4 nitrogen atoms in the ring; R1 is independently at each occurrence H, alkyl, or halogen, provided that at least one occurrence of R1 comprises tritium or a halogen radioisotope], useful as ligands for nicotinic acetylcholine receptor. For instance, deuterium-labeled fluorophenylspiro(azabicyclooctane-furopyridine) derivative II was prepared from (tribromofluorophenyl)spiro(azabicyclooctane-furopyridine) derivative III and deuterium gas in the presence of palladium. The invention compds. were tested in α7 and α4 nAChR affinity assays and showed binding

affinities (Ki) of less than 1000 nM.
AN 2005:300454 CAPLUS
DN 142:373816
TI A preparation of isotope-labeled spiro(azabicyclooctane-furopyridine) derivatives, useful as ligands for nicotinic acetylcholine receptor
IN Dorff, Peter; Gordon, John; Heys, John Richard; Keith, Richard A.; McCarthy, Dennis J.; Phillips, Eifion; Smith, Mark A.
PA Astrazeneca AB, Swed.; Astrazeneca UK Ltd.
SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030778	A1	20050407	WO 2004-GB4116	20040924
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004276061	A1	20050407	AU 2004-276061	20040924
	CA 2538705	A1	20050407	CA 2004-2538705	20040924
	EP 1668016	A1	20060614	EP 2004-768659	20040924
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1856497	A	20061101	CN 2004-80027711	20040924
	BR 2004014633	A	20061107	BR 2004-14633	20040924
	JP 2007506719	T	20070322	JP 2006-527486	20040924
	NZ 546414	A	20090731	NZ 2004-546414	20040924
	CN 101052637	A	20071010	CN 2005-80031826	20050922
	MX 2006003196	A	20060623	MX 2006-3196	20060322
	ZA 2006002445	A	20070926	ZA 2006-2445	20060324
	NO 2006001819	A	20060626	NO 2006-1819	20060425
	US 20070172420	A1	20070726	US 2007-573133	20070112
	AU 2009200802	A1	20090319	AU 2009-200802	20090227
PRAI	US 2003-505731P	P	20030925		
	AU 2004-276061	A3	20040924		
	WO 2004-GB4112	A	20040924		
	WO 2004-GB4116	W	20040924		
	US 2004-640309P	P	20041230		
	WO 2005-SE1404	W	20050922		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 142:373816; MARPAT 142:373816
IT 849434-95-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of isotope-labeled spiro(azabicyclooctane-furopyridine) derivs. useful as ligands for nicotinic acetylcholine receptor)

RN 849434-95-3 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-fluorophenyl)-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
AB The present invention relates to radiolabeled compds. particularly 1-azabicyclo [2.2.2]octane compds. (i.e., quinuclidine compds.) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the α7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compds. of the invention, particularly tissues, organs, or tumors which express a7-nicotinic cholinergic receptor to which the compds. of the invention have an affinity.
AN 2005:14173 CAPLUS
DN 142:88902
TI Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor
IN Pomper, Martin G.; Musachio, John L.; Fan, Hong; Dannals, Robert F.; Foss, Catherine; Phillips, Eifion; Gordon, Jack; McCarthy, Dennis; Keith, Richard; Smith, Mark; Heys, Dick; Dorf, Peter
PA Johns Hopkins University, USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005000250	A2	20050106	WO 2004-US20530	20040624
WO 2005000250	A3	20060323		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20050129610 A1 20050616 US 2004-877813 20040624

PRAI US 2003-482108P P 20030624

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 142:88902

IT 816462-90-5

RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)

(imaging agents for α7-nicotinic receptors)

RN 816462-90-5 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-[2-(fluoro-18F)phenyl]-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN

AB (R)-(+)-5'-phenylspiro-1-azabicyclo[2.2.2] octane-3,3'(3'H)-furo[2,3-b]pyridine (PSAB-OFP) in a battery of behavioral assays in the rat was evaluated. Results indicated that PSAB-OPF slightly but significantly decreased spontaneous locomotor activity 20-40 min after injection-(20% decrease at 10 mg/kg), but failed to alter stimulant-induced activity, and ketamine-induced disruption of prepulse inhibition, and had no effect in the forced swim test or ultrasonic vocalization. The compound also failed to alter cognitive performance in the eight-arm radial maze and had no functional or neuroprotective actions in the 6-hydroxy-dopamine (6-OHDA) model. PSAB-OFP was thus inactive in a wide range of behavioral assays. It is not clear whether this reflects a relatively unimportant role for the α7 receptor in behavioral processes; insufficient exposure of the receptor to the compound; rapid receptor desensitization, and/or a significantly lower affinity for rodent native receptors compared with human recombinant α7 receptors.

AN 2004:936884 CAPLUS

DN 142:127838

TI Brain penetration and behavioral properties of a potent α7 nicotinic acetylcholine receptor agonist in the rat

AU Moore, N. A.; McKinzie, D. L.; Mitchell, S. N.; Keenan, M.; Dobson, D. R.; Wishart, G.; O'Neill, M. F.; Murray, T. K.; Tree, B.; Iyengar, S.; Hart, J.; Shaw, D.; Simmons, R. M. A.; Kalra, A. B.; Miles, C.; Conway, M.; Boot, J. R.; Baker, S. R.; Sher, E.; Tricklebank, M. D.; O'Neill, M. J.

CS Lilly Research Centre, Eli Lilly & Co. Ltd, Windlesham, Surrey, UK

SO Cholinergic Mechanisms: Function and Dysfunction, [International Symposium

on Cholinergic Mechanisms], 11th, St. Moritz, Switzerland, May 5-9, 2002 (2004), Meeting Date 2002, 649-650. Editor(s): Silman, Israel. Publisher: Taylor & Francis Ltd., London, UK.
CODEN: 69GBA2; ISBN: 1-84184-075-0
DT Conference
LA English
IT 521288-83-5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(brain penetration and behavioral properties of a potent α7 nicotinic acetylcholine receptor agonist in rat)
RN 521288-83-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
AB Methods of inhibiting release of a proinflammatory cytokine from a macrophage are provided. The methods comprise treating the macrophage with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the macrophage, wherein the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for inhibiting an inflammatory cytokine cascade in a patient are also provided. The methods comprise treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for determining whether a compound is a cholinergic agonist reactive with an α7 nicotinic receptor are also provided. The methods comprise determining whether the compound inhibits release of a proinflammatory cytokine from a mammalian cell. Addnl., methods for determining whether a compound is a cholinergic antagonist reactive with an α7 nicotinic receptor are provided. These methods comprise determining whether the compound reduces the ability of a cholinergic agonist to inhibit the release of a proinflammatory cytokine from a mammalian cell. Oligonucleotides or mimetics capable of inhibiting attenuation of lipopolysaccharide-induced TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are also provided. The oligonucleotides or mimetics consist essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 receptor. Addnl., methods of inhibiting attenuation of TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are provided. These methods comprise treating the macrophage with the above-described oligonucleotide or mimetic. Sepsis in mice was

treated with 3-(2,4-dimethoxybenzylidene)anabaseine.
AN 2004:513538 CAPLUS
DN 141:65099
TI Inhibition of inflammation using α7 nicotinic receptor-binding cholinergic agonists
IN Tracey, Kevin J.; Wang, Hong
PA North Shore-Long Island Jewish Research Institute, USA
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052365	A2	20040624	WO 2003-US38708	20031205
	WO 2004052365	A3	20040923		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2507502	A1	20040624	CA 2003-2507502	20031205
	AU 2003298939	A1	20040630	AU 2003-298939	20031205
	AU 2003298939	B2	20070315		
	EP 1581223	A2	20051005	EP 2003-796701	20031205
	EP 1581223	B1	20071114		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1735414	A	20060215	CN 2003-80108261	20031205
	JP 2006514946	T	20060518	JP 2004-559325	20031205
	AT 378048	T	20071115	AT 2003-796701	20031205
	ES 2293086	T3	20080316	ES 2003-796701	20031205
	EP 1949901	A2	20080730	EP 2007-20473	20031205
	EP 1949901	A3	20081015		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	EP 2062595	A1	20090527	EP 2009-1425	20031205
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	IN 2005DN02359	A	20061229	IN 2005-DN2359	20050602
PRAI	US 2002-431650P	P	20021206		
	EP 2003-796701	A3	20031205		
	EP 2007-20473	A3	20031205		
	WO 2003-US38708	W	20031205		

OS MARPAT 141:65099
IT 220099-94-5
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as cholinergic agonist of α7 nicotinic receptor; inflammation inhibition with α7 nicotinic receptor-binding cholinergic agonists)

RN 220099-94-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
AB The invention discloses combinations of α7-nAChR agonists and statins, pharmaceutical compns. containing them, and methods of using them for the treatment or prophylaxis of neurol. degenerative diseases.
AN 2004:203672 CAPLUS
DN 140:229466
TI α7-Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases
IN Keith, Richard
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004019947	A1	20040311	WO 2003-SE1352	20030901
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003256203	A1	20040319	AU 2003-256203	20030901
	EP 1545537	A1	20050629	EP 2003-791540	20030901
	EP 1545537	B1	20070404		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006505530	T	20060216	JP 2004-532517	20030901
	AT 358485	T	20070415	AT 2003-791540	20030901
	PT 1545537	E	20070620	PT 2003-791540	20030901
	ES 2283860	T3	20071101	ES 2003-791540	20030901
	US 20050256146	A1	20051117	US 2005-525783	20050228
	HK 1077193	A1	20070921	HK 2005-109104	20051014

US 20090192180 A1 20090730 US 2008-186915 20080806
PRAI SE 2002-2598 A 20020902
WO 2003-SE1352 W 20030901
US 2005-525783 B1 20050228
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
IT 220099-94-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α7-nicotinic receptor agonists and statins in combination for treatment of neurodegenerative diseases)
RN 220099-94-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
AB The invention discloses a method for treating fibromyalgia syndrome and fibromyalgia-related symptoms with an agonist of α7 nicotinic acetylcholine receptors.
AN 2003:319637 CAPLUS
DN 138:314632
TI Agonists of α7 nicotinic acetylcholine receptors for the treatment of fibromyalgia syndrome
IN McCarthy, Dennis; Gurley, David
PA AstraZeneca AB, Swed.
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032897	A2	20030424	WO 2002-SE1887	20021015
	WO 2003032897	A3	20031113		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2002339810 A1 20030428 AU 2002-339810 20021015
EP 1453828 A2 20040908 EP 2002-778156 20021015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
JP 2005510482 T 20050421 JP 2003-535703 20021015
US 20040259909 A1 20041223 US 2004-492891 20040416
PRAI SE 2001-3463 A 20011016
SE 2002-1033 A 20020404
WO 2002-SE1887 W 20021015
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 138:314632
IT 220099-94-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α7 nicotinic agonists for treatment of fibromyalgia syndrome)
RN 220099-94-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
AB 5-Hydroxytryptamine 3 (5-HT3) and α7 nicotinic receptors share high sequence homol. and pharmacol. cross-reactivity. An assessment of the potential role of α7 receptors in many neurophysiol. processes, and hence their therapeutic value, requires the development of selective α7 receptor agonists. The authors used a recently reported selective α7 receptor agonist, (R)-(-)-5'-phenylspiro-1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine (PSAB-OFP) and confirmed its activity on human recombinant α7 receptors. However, PSAB-OFP also displayed high affinity binding to 5-HT3 receptors. To assess the functional activity of PSAB-OFP on 5-HT3 receptors the authors studied recombinant human 5-HT3 receptors expressed in Xenopus oocytes, as well as native mouse 5-HT3 receptors expressed in N1E-115 neuroblastoma cells, using whole-cell patch clamp and Ca2+ imaging. The authors' results show that PSAB-OFP is an equipotent, partial agonist of both α7 and 5-HT3 receptors. The authors conclude that it will be necessary to identify the determinant of this overlapping pharmacol. to develop more selective α7 receptor ligands.
AN 2002:725234 CAPLUS
DN 138:362501
TI PSAB-OFP, a selective α7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor
AU Broad, Lisa M.; Felthouse, Catherine; Zwart, Ruud; McPhie, Gordon I.;

Pearson, Kathy H.; Craig, Peter J.; Wallace, Louise; Broadmore, Richard J.; Boot, John R.; Keenan, Martine; Baker, S. Richard; Sher, Emanuele
CS Lilly Research Centre, Eli Lilly and Company Limited, Windlesham, GU20 6PH, UK
SO European Journal of Pharmacology (2002), 452(2), 137-144
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 521288-83-5
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PSAB-OFP, a selective α7 nicotinic receptor agonist, is also a 5-HT3 receptor agonist)
RN 521288-83-5 CAPLUS
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



OSC.G 28 THERE ARE 28 CAPLUS RECORDS THAT CITE THIS RECORD (28 CITINGS)
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I



II

AB Title compds. (I; A = N or CR2; D = N or CR4; G = N or CR3; R2-R4 = H, halo, alkyl, alkoxy, etc.; W = O, H2, F2; X = O or S; Y = CH, N, NO; each Z, independently, may be bond or CH2) were prepared Thus, 3-quinuclidinone was cyclocondensed with Me3S(O)I and the N-BH3-complexed product condensed with 2-chloropyridine to give, after cyclization and decomplexation, title compound II.
AN 1999:77567 CAPLUS
DN 130:139332

TI Preparation of spiro[azabicyclo-furopyridine] derivatives and analogs as α7 nicotinic receptor agonists
IN Phillips, Eifion; Mack, Robert; Macor, John; Semus, Simon
PA Astra Aktiebolag, Swed.
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9903859	A1	19990128	WO 1998-SE1364	19980710
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9805995	A	19990803	ZA 1998-5995	19980707
CA 2296031	A1	19990128	CA 1998-2296031	19980710
CA 2296031	C	20080108		
AU 9883679	A	19990210	AU 1998-83679	19980710
AU 739022	B2	20011004		
EP 996622	A1	20000503	EP 1998-934078	19980710
EP 996622	B1	20021009		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000129	T2	20000721	TR 2000-129	19980710
BR 9810924	A	20000815	BR 1998-10924	19980710
EE 200000031	A	20001016	EE 2000-31	19980710
EE 4399	B1	20041215		
HU 2000003844	A2	20010730	HU 2000-3844	19980710
HU 2000003844	A3	20021128		
JP 2001510194	T	20010731	JP 2000-503083	19980710
NZ 502298	A	20020201	NZ 1998-502298	19980710
EP 1213291	A1	20020612	EP 2002-5982	19980710
EP 1213291	B1	20041201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 225792	T	20021015	AT 1998-934078	19980710
PT 996622	E	20030131	PT 1998-934078	19980710
ES 2185185	T3	20030416	ES 1998-934078	19980710
RU 2202553	C2	20030420	RU 2000-103958	19980710
SK 283484	B6	20030805	SK 1999-1835	19980710
CN 1117755	C	20030813	CN 1998-809055	19980710
AT 283859	T	20041215	AT 2002-5982	19980710
ES 2231599	T3	20050516	ES 2002-5982	19980710
PL 193065	B1	20070131	PL 1998-338259	19980710
IL 134086	A	20070819	IL 1998-134086	19980710
IN 1998DE01989	A	20070831	IN 1998-DE1989	19980710
TW 515799	B	20030101	TW 1998-87111679	19980717
US 6110914	A	20000829	US 1998-171983	19981029
MX 2000000461	A	20010629	MX 2000-461	20000112
NO 2000000226	A	20000314	NO 2000-226	20000117

	NO 325324	B1	20080331		
	US 6369224	B1	20020409	US 2000-594703	20000616
	HK 1025322	A1	20030425	HK 2000-104490	20000720
	HK 1031382	A1	20040227	HK 2001-102261	20010328
	US 20020187994	A1	20021212	US 2002-93939	20020308
	US 6703502	B2	20040309		
	HK 1046274	A1	20050520	HK 2002-107504	20021016
	US 20030166935	A1	20030904	US 2003-396215	20030324
	US 6706878	B2	20040316		
	US 20050004099	A1	20050106	US 2004-801085	20040315
	US 7507744	B2	20090324		
	US 20080153864	A1	20080626	US 2008-47425	20080313
PRAI	SE 1997-2746	A	19970718		
	SE 1998-977	A	19980324		
	EP 1998-934078	A3	19980710		
	WO 1998-SE1364	W	19980710		
	US 1998-171983	A3	19981029		
	US 2000-594703	A1	20000616		
	US 2002-93939	A3	20020308		
	US 2003-396215	A3	20030324		
	US 2004-801085	A1	20040315		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 130:139332

IT 220099-94-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiro[azabicyclo-furopyridine] derivs. and analogs as α7 nicotinic receptor agonists)

RN 220099-94-5 CAPLUS

CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl- (CA INDEX NAME)



OSC.G 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT